Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group (original) (raw)

Abstract

Purpose: Tomudex is a second-generation folate analogue that when polyglutamated is a potent inhibitor of thymidylate synthase (TS). Methods: Based on indications of antitumor activity in phase I trials, the Gynecologic Oncology Group initiated a phase II study of Tomudex 3 mg/m2 intravenously every 3 weeks in patients with epithelial ovarian cancer, who had been pretreated with platinum drugs, and had subsequently recurred more than 6 months following such treatment. Results: Of 30 patients entered into the trial, 2 were pathologically ineligible, leaving 28 fully evaluable. In this patient population, Tomudex was generally well tolerated, but only three objective (partial) responses were documented. Conclusions: With the level of activity seen, the drug was not considered for further clinical development in ovarian cancer by the Gynecologic Oncology Group. However, it may be worthwhile to explore whether quantitation of TS could lead to selection of patients more likely to respond to this TS inhibitor.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Department of Medicine and Medical Oncology, Kaplan Cancer Center, New York University Medical Center, 550 First Avenue, New York, NY 10016, USA Tel. +1-212-263-6484; Fax +1-212-263-8210, , , , , , US
    Franco M. Muggia
  2. Gynecologic Oncology Group, Roswell Park Cancer Institute, Buffalo, NY 14263, USA, , , , , , US
    John A. Blessing
  3. Bowman Gray School of Medicine, Carolina Gynecologic Oncology, Winston-Salem, NC 27103, USA, , , , , , US
    Howard D. Homesley
  4. Division of Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA, , , , , , US
    Joel Sorosky

Authors

  1. Franco M. Muggia
    You can also search for this author inPubMed Google Scholar
  2. John A. Blessing
    You can also search for this author inPubMed Google Scholar
  3. Howard D. Homesley
    You can also search for this author inPubMed Google Scholar
  4. Joel Sorosky
    You can also search for this author inPubMed Google Scholar

Additional information

Received: 22 May 1997 / Accepted: 8 October 1997

Rights and permissions

About this article

Cite this article

Muggia, F., Blessing, J., Homesley, H. et al. Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group.Cancer Chemother Pharmacol 42, 68–70 (1998). https://doi.org/10.1007/s002800050786

Download citation